HRP20210245T1 - Primjena fk506 za liječenje plućne arterijske hipertenzije - Google Patents
Primjena fk506 za liječenje plućne arterijske hipertenzije Download PDFInfo
- Publication number
- HRP20210245T1 HRP20210245T1 HRP20210245TT HRP20210245T HRP20210245T1 HR P20210245 T1 HRP20210245 T1 HR P20210245T1 HR P20210245T T HRP20210245T T HR P20210245TT HR P20210245 T HRP20210245 T HR P20210245T HR P20210245 T1 HRP20210245 T1 HR P20210245T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- arterial hypertension
- pulmonary arterial
- use according
- subject
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 9
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 claims 4
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 claims 4
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000012085 Endoglin Human genes 0.000 claims 2
- 108010036395 Endoglin Proteins 0.000 claims 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Claims (8)
1. Spoj FK506 za primjenu u liječenju plućne arterijske hipertenzije kod ljudskog subjekta koji ima plućnu arterijsku hipertenziju koja je u vezi sa neispravnom BMPR2 signalizacijom, pri čemu se FK506 administrira u dozi koja osigurava koncentraciju u krvi ispod 5 ng/ml.
2. Spoj za primjenu prema patentnom zahtjevu 1, pri čemu subjekt ima smanjeno eksprimiranje BMPR2, ALK1 ili endoglina.
3. Spoj za primjenu prema patentnom zahtjevu 1, pri čemu subjekt ima nasljednu plućnu arterijsku hipertenziju uzrokovanu mutacijom u BMPR2.
4. Spoj za primjenu prema patentnom zahtjevu 1, pri čemu subjekt ima nasljednu plućnu arterijsku hipertenziju uzrokovanu mutacijom u ALK1.
5. Spoj za primjenu prema patentnom zahtjevu 1, pri čemu subjekt ima nasljednu plućnu arterijsku hipertenziju uzrokovanu mutacijom u endoglinu.
6. Spoj za primjenu prema patentnom zahtjevu 1, pri čemu doza osigurava koncentraciju FK506 u krvi od 0,1 - 0,2 ng/ml.
7. Spoj za primjenu prema patentnom zahtjevu 1, pri čemu se spoj administrira oralno.
8. Spoj FK506 za primjenu u prevenciji plućne arterijske hipertenzije koja je u vezi sa neispravnom BMPR2 signalizacijom kod ljudskog subjekta, pri čemu se FK506 administrira u dozi koja osigurava koncentraciju u krvi ispod 5 ng/ml.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481317P | 2011-05-02 | 2011-05-02 | |
| PCT/US2012/035793 WO2012151153A1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
| EP12779354.5A EP2704711B1 (en) | 2011-05-02 | 2012-04-30 | Use of fk506 for the treatment of pulmonary arterial hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210245T1 true HRP20210245T1 (hr) | 2021-04-02 |
Family
ID=47108011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210245TT HRP20210245T1 (hr) | 2011-05-02 | 2021-02-12 | Primjena fk506 za liječenje plućne arterijske hipertenzije |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9474745B2 (hr) |
| EP (3) | EP3821891B1 (hr) |
| JP (1) | JP6177765B2 (hr) |
| AU (2) | AU2012250974B9 (hr) |
| CA (1) | CA2834368C (hr) |
| CY (1) | CY1123900T1 (hr) |
| DK (2) | DK3821891T3 (hr) |
| ES (2) | ES2856173T3 (hr) |
| FI (1) | FI3821891T3 (hr) |
| HR (1) | HRP20210245T1 (hr) |
| HU (1) | HUE053229T2 (hr) |
| LT (1) | LT2704711T (hr) |
| PL (1) | PL2704711T3 (hr) |
| PT (2) | PT3821891T (hr) |
| RS (1) | RS61480B1 (hr) |
| SI (1) | SI2704711T1 (hr) |
| WO (1) | WO2012151153A1 (hr) |
| ZA (1) | ZA201307905B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6890540B2 (ja) * | 2015-01-13 | 2021-06-18 | バイバス・インコーポレイテッドＶｉｖｕｓ， Ｉｎｃ． | 肺高血圧症のための併用療法 |
| CA2985080A1 (en) * | 2015-05-08 | 2016-11-17 | Vivus, Inc. | Compositions and methods for the treatment or prevention of pulmonary hypertension |
| CN105062976B (zh) * | 2015-08-05 | 2018-05-11 | 中国医学科学院基础医学研究所 | 肺动脉高压治疗药物的干细胞筛选模型及应用 |
| ES2683921B1 (es) * | 2017-03-28 | 2019-04-22 | Univ Vigo | Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar |
| US11413280B2 (en) | 2017-05-19 | 2022-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension |
| EP3773571A1 (en) * | 2018-03-28 | 2021-02-17 | Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin | Prevention or treatment of chronic organ injury |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| JP5506378B2 (ja) | 2006-03-23 | 2014-05-28 | 参天製薬株式会社 | 血管透過性に関連する疾患または病気のための製剤および方法 |
| FR2936060B1 (fr) * | 2008-09-17 | 2010-11-19 | Assist Publ Hopitaux De Paris | Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire. |
| AU2009307901A1 (en) * | 2008-10-22 | 2010-04-29 | Ventrus Biosciences, Inc. | Method for treating pulmonary arterial hypertension |
-
2012
- 2012-04-30 EP EP20211109.2A patent/EP3821891B1/en active Active
- 2012-04-30 WO PCT/US2012/035793 patent/WO2012151153A1/en active Application Filing
- 2012-04-30 DK DK20211109.2T patent/DK3821891T3/da active
- 2012-04-30 JP JP2014509338A patent/JP6177765B2/ja active Active
- 2012-04-30 SI SI201231881T patent/SI2704711T1/sl unknown
- 2012-04-30 PT PT202111092T patent/PT3821891T/pt unknown
- 2012-04-30 PL PL12779354T patent/PL2704711T3/pl unknown
- 2012-04-30 RS RS20210239A patent/RS61480B1/sr unknown
- 2012-04-30 LT LTEP12779354.5T patent/LT2704711T/lt unknown
- 2012-04-30 HU HUE12779354A patent/HUE053229T2/hu unknown
- 2012-04-30 ES ES12779354T patent/ES2856173T3/es active Active
- 2012-04-30 CA CA2834368A patent/CA2834368C/en active Active
- 2012-04-30 EP EP12779354.5A patent/EP2704711B1/en active Active
- 2012-04-30 EP EP23177834.1A patent/EP4279130A3/en active Pending
- 2012-04-30 US US14/113,375 patent/US9474745B2/en active Active
- 2012-04-30 AU AU2012250974A patent/AU2012250974B9/en active Active
- 2012-04-30 FI FIEP20211109.2T patent/FI3821891T3/fi active
- 2012-04-30 PT PT127793545T patent/PT2704711T/pt unknown
- 2012-04-30 ES ES20211109T patent/ES2954905T3/es active Active
- 2012-04-30 DK DK12779354.5T patent/DK2704711T3/da active
-
2013
- 2013-10-23 ZA ZA2013/07905A patent/ZA201307905B/en unknown
-
2016
- 2016-09-21 US US15/271,794 patent/US20170007585A1/en not_active Abandoned
-
2017
- 2017-08-03 AU AU2017210583A patent/AU2017210583B2/en active Active
- 2017-10-12 US US15/782,153 patent/US20180185340A1/en not_active Abandoned
-
2018
- 2018-11-21 US US16/198,242 patent/US20190091208A1/en not_active Abandoned
-
2020
- 2020-07-29 US US16/941,778 patent/US20220184042A1/en not_active Abandoned
-
2021
- 2021-02-12 HR HRP20210245TT patent/HRP20210245T1/hr unknown
- 2021-02-23 CY CY20211100151T patent/CY1123900T1/el unknown
-
2023
- 2023-01-06 US US18/151,028 patent/US20230404982A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210245T1 (hr) | Primjena fk506 za liječenje plućne arterijske hipertenzije | |
| CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| HRP20170848T1 (hr) | Kompozicije i metode za liječenje pluće hipertenzije | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| EA201491339A1 (ru) | Замещенные аннеллированные пиримидины и триазины и их применение | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| EA201490540A1 (ru) | Соединения и композиции в качестве ингибиторов с-kit киназы | |
| GT201300243A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
| WO2014004993A3 (en) | Methods of reducing ldl-p | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| EA201590251A1 (ru) | Новые 5-аминотетрагидрохинолин-2-карбоновые кислоты и их применение | |
| WO2012094598A3 (en) | Pharmaceutical compositions of iron for oral administration | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| EA201590562A1 (ru) | Бензамиды | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| BR112015010136A2 (pt) | derivados de oxazolidin-2-ona-pirimidina | |
| JP2014513121A5 (hr) | ||
| BR112013027486A2 (pt) | combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| BR112015001056A2 (pt) | composto, composição farmacêutica, métodos para o tratamento de distúrbios mediados pela aldosterona, para o tratamento de doença ou uma condição, para o tratamento da síndrome metabólica, para o tratamento de uma doença fisiológica ou patológica e para o tratamento da doença renal crônica, insuficiência renal ou nefropatia diabética | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| EA201390844A1 (ru) | Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения | |
| PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
| AR097890A1 (es) | Compuestos de urea |